Quick Answer
Actinium Pharmaceuticals, Inc. reported Total Revenue of $90.0 thousand for fiscal year 2025.
Actinium Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $90.0K | — | $81.0K -92.1% |
$1.03M -10.0% |
$1.14M | — |
| Net Income | -$33.89M +11.4% |
-$38.24M +21.7% |
-$48.82M -47.9% |
-$33.02M -33.3% |
-$24.77M -11.5% |
-$22.21M -1.4% |
| Diluted EPS | -$1.09 +14.2% |
-$1.27 +30.6% |
-$1.83 -33.6% |
-$1.37 -14.2% |
-$1.20 | — |
| Total Assets | $51.77M -32.7% |
$76.90M -5.6% |
$81.44M -28.7% |
$114.19M +42.1% |
$80.39M +21.1% |
$66.40M +469.0% |
| Cash and Equivalents | $48.00M -34.2% |
$72.90M -4.9% |
$76.68M -29.6% |
$108.91M +39.9% |
$77.83M +22.4% |
$63.56M +586.8% |
| Stockholders Equity | $7.83M -76.1% |
$32.76M -10.0% |
$36.38M -45.3% |
$66.48M -9.6% |
$73.55M +19.9% |
$61.32M +986.4% |
| R&D Expense | $21.12M -29.7% |
$30.05M -22.3% |
$38.67M +67.1% |
$23.14M +28.3% |
$18.03M +12.1% |
$16.09M -2.8% |
| Operating Income | -$36.25M +13.9% |
-$42.12M +18.9% |
-$51.92M -52.2% |
-$34.10M -36.6% |
-$24.96M -11.5% |
-$22.39M -1.5% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 31.20M +0.0% |
31.20M +12.9% |
27.63M +7.6% |
25.67M +15.9% |
22.14M +26.3% |
17.53M +219.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $90.0K | — | +100.0% |
| Net Income | September 30, 2025 | -$5.13M | +55.6% | +25.4% |
| Diluted EPS | September 30, 2025 | -$0.16 | +56.8% | +27.3% |
| Total Assets | September 30, 2025 | $56.15M | -31.6% | -10.9% |
| Cash and Equivalents | September 30, 2025 | $53.39M | -32.1% | -10.9% |
| Stockholders Equity | September 30, 2025 | $13.78M | -63.9% | -27.5% |
| R&D Expense | September 30, 2025 | $4.25M | -56.5% | -12.9% |
| Operating Income | September 30, 2025 | -$5.69M | +54.8% | +24.1% |
| Gross Profit | March 31, 2012 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 31.20M | +0.0% | +0.0% |
- Actinium Pharmaceuticals, Inc. reported Total Revenue of $90.0 thousand for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +11.1% in Total Revenue compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Net Income of -$33.89 million for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +11.4% in Net Income compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Diluted EPS of $1.09 per share (loss) for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +14.2% in Diluted EPS compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Total Assets of $51.77 million for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed a decrease of -32.7% in Total Assets compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Cash and Equivalents of $48.00 million for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed a decrease of -34.2% in Cash and Equivalents compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Stockholders Equity of $7.83 million for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed a decrease of -76.1% in Stockholders Equity compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported R&D Expense of $21.12 million for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed a decrease of -29.7% in R&D Expense compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Operating Income of -$36.25 million for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +13.9% in Operating Income compared to the prior fiscal year.
- Actinium Pharmaceuticals, Inc. reported Gross Profit of $0.00 for fiscal year 2011.
- Actinium Pharmaceuticals, Inc. reported Shares Outstanding of 31.20 million shares for fiscal year 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: